Alkermes (NASDAQ:ALKS) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Alkermes (NASDAQ:ALKS) had its target price boosted by research analysts at Wells Fargo & Company from $37.00 to $43.00 in a research note issued on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 42.86% from the company’s previous close.

Several other equities research analysts have also weighed in on the company. Royal Bank Of Canada reduced their price objective on Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. HC Wainwright reaffirmed a “neutral” rating and issued a $43.00 price target on shares of Alkermes in a research note on Thursday. Truist Financial raised their price objective on shares of Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Bank of America upped their price target on Alkermes from $33.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alkermes presently has an average rating of “Moderate Buy” and a consensus price target of $44.07.

Alkermes Stock Down 2.1%

ALKS stock opened at $30.10 on Thursday. Alkermes has a fifty-two week low of $25.17 and a fifty-two week high of $36.32. The company has a market capitalization of $5.02 billion, a P/E ratio of 21.05 and a beta of 0.49. The company has a 50-day simple moving average of $31.54 and a 200 day simple moving average of $30.20.

Alkermes (NASDAQ:ALKS) last announced its earnings results on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.14). Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The firm had revenue of $384.55 million for the quarter, compared to the consensus estimate of $380.44 million. During the same period in the previous year, the firm earned $1.05 EPS. Alkermes’s revenue for the quarter was down 10.6% on a year-over-year basis. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. Equities analysts anticipate that Alkermes will post 1.31 EPS for the current year.

Insider Transactions at Alkermes

In related news, Director Shane Cooke sold 61,200 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total value of $2,115,684.00. Following the completion of the transaction, the director directly owned 103,744 shares in the company, valued at approximately $3,586,430.08. This represents a 37.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $33.93, for a total transaction of $305,370.00. Following the transaction, the executive vice president directly owned 57,740 shares of the company’s stock, valued at $1,959,118.20. The trade was a 13.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 148,148 shares of company stock valued at $5,028,378 in the last ninety days. 4.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alkermes

Several large investors have recently modified their holdings of ALKS. Baker BROS. Advisors LP raised its stake in Alkermes by 23.7% during the fourth quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company’s stock worth $280,143,000 after acquiring an additional 1,920,916 shares in the last quarter. State Street Corp increased its holdings in shares of Alkermes by 10.9% in the fourth quarter. State Street Corp now owns 9,472,858 shares of the company’s stock valued at $265,051,000 after purchasing an additional 932,507 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Alkermes by 6.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,668,028 shares of the company’s stock valued at $186,571,000 after buying an additional 375,500 shares during the period. JPMorgan Chase & Co. increased its position in Alkermes by 32.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company’s stock worth $145,064,000 after purchasing an additional 1,256,377 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Alkermes by 19.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,412,783 shares of the company’s stock worth $123,467,000 after buying an additional 714,787 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors.

Key Headlines Impacting Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analyst optimism — Wells Fargo raised its price target to $43 and kept an overweight stance, signaling bullish analyst conviction that shares have meaningful upside. Wells Fargo raises price target to $43
• Positive Sentiment: RBC still rates ALKS “outperform” and keeps a high price target ($45 after a small cut), indicating continued buy-side support from some sell-side analysts. RBC maintains outperform, lowers PT to $45
• Neutral Sentiment: CEO succession announced — Alkermes disclosed a leadership transition plan; such changes create short-term uncertainty but may be neutral-to-positive over time depending on execution. Alkermes announces CEO succession plan
• Neutral Sentiment: Revenue roughly in line/beat estimates while EPS missed — top-line results were not the primary problem; profitability and EPS dynamics drove the negative reaction. See earnings highlights and call transcript for detail. Q4 2025 earnings highlights
• Negative Sentiment: Earnings miss and downbeat near-term outlook — reported EPS (~$0.29) missed the ~$0.43 consensus and management set FY2026 EPS guidance in negative territory, undercutting the bull case and spurring the sell-off. Shares down after earnings miss
• Negative Sentiment: Market reaction — shares declined sharply on the news and trading volume picked up, reflecting short-term repositioning by investors. Coverage pieces and call transcripts detail investor pushback. ALKS down despite mixed results, leadership change
• Neutral Sentiment: Short-interest reporting in feeds shows inconclusive/zeroed data for February (no actionable signal from that dataset). Short interest note

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.